F. Germini, C. Cossa, E. Trinari, et al. “ Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources.” Haemophilia (2025): . https://doi.org/10.1111/hae.70117 Introduction The Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire can be used to measure quality of life in persons with… Continue reading Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources
Tag: 2023
Gene Therapy in Hemophilia A: the Impact of Valoctocogene Roxaparvovec on Patient Outcomes – Initial Results from Patient Reported Outcomes, Burdens and Experiences (PROBE) from the GENEr8-1 Trial
Skinner M, Chen E, Ibrahim Q, Kucher A, Germini F, Karimi M, Clearfield E , O’Mahony B , Jain M. Gene Therapy in Hemophilia A: the Impact of Valoctocogene Roxaparvovec on Patient Outcomes – Initial Results from Patient Reported Outcomes, Burdens and Experiences (PROBE) from the GENEr8-1 Trial. (Abstract). NHF (2023). Objective The Patient Reported… Continue reading Gene Therapy in Hemophilia A: the Impact of Valoctocogene Roxaparvovec on Patient Outcomes – Initial Results from Patient Reported Outcomes, Burdens and Experiences (PROBE) from the GENEr8-1 Trial
Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE
Skinner M, Chen E, Kucher A, Germini F, Karimi M, Clearfield E , O’Mahony B , Jain M. Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE. (Abstract). NHF (2023). Introduction People with severe haemophilia A (PwSHA) commonly present with intramuscular bleeding and hemarthrosis, leading to acute and chronic… Continue reading Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE
Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE
Skinner M, Chen E, Kucher A, Germini F, Karimi M, Clearfield E , O’Mahony B , Jain M. Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE. (2023), CCS_Book of abstracts. Haemophilia, 29: 3-53. https://doi.org/10.1111/hae.14781 Introduction People with severe haemophilia A (PwSHA) commonly present with intramuscular bleeding and hemarthrosis,… Continue reading Initial results of the impact of valoctocogene roxaparvovec on pain occurrence and interference: Insights from PROBE
Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study
Curtis R, Wu J, Iorio A, Nichol M, Germini F, Kucher A, Skinner M. Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study. (2023), POSTER ABSTRACTS (PO077). Haemophilia, 29: 24-202. https://doi.org/10.1111/hae.14715 Objective To investigate the test-retest reliability of the PROBE questionnaire mobile application (MyPROBE). Methods People with hemophilia (PWH) including carriers… Continue reading Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study
Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study
Curtis R, Wu J, Iorio A, Nichol M, Germini F, Kucher A, Skinner M. Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study. (2023), POSTER ABSTRACTS (PO077). Haemophilia, 29: 24-202. https://doi.org/10.1111/hae.14715 Objective To investigate the test-retest reliability of the PROBE questionnaire mobile application (MyPROBE). Methods People with hemophilia (PWH) including carriers… Continue reading Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study
Impact on Pain and Activities of Daily Living after Switching to Emicizumab: Insight from PROBE
Kucher A, Clearfield E, Germini F, Dubé E, Merlen C, Bonnefoy A, St-Louis J, Rivard G.E, Skinner M. Impact on Pain and Activities of Daily Living after Switching to Emicizumab: Insight from PROBE.(2023), POSTER ABSTRACTS (PO177). Haemophilia, 29: 24-202. https://doi.org/10.1111/hae.14715 Introduction Emicizumab for treatment of people with severe hemophilia A (SHA) was recently approved by… Continue reading Impact on Pain and Activities of Daily Living after Switching to Emicizumab: Insight from PROBE
